In vitro-in vivo correlations: Tricks and traps

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 491-499

  Cardot, J M ^a   Davit, B M ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

biowaiver; in vitro in vivo correlation (IVIVC); predictability; prediction; time scaling

Indexed keywords

ACCURACY; ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; CORRELATIONAL STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FIRST PASS EFFECT; FLIP FLOP MODEL; IN VITRO IN VIVO CORRELATION; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; PHARMACEUTICS; PREDICTION; REACTION TIME; SIMULATION; VALIDATION PROCESS;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; MODELS, THEORETICAL;

EID: 84862766980     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9359-0     Document Type: Article

References (38)

1. JM Cardot E Beyssac 1993 In vitro/in vivo correlations: scientific implications and standardisation Eur J Drug Met Ph 18 113 120 10.1007/BF03220014 1:CAS:528:DyaK3sXlslentLY%3D
2. Cardot J-M, Beyssac E. In vitro/in vivo correlations in: James Swarbrick, James C. Boylan editors. Encyclopedia of Pharmaceutical Technology 3rd ed, Informa healthcare; 2006. vol 1 p.1062-1072.
3. J Devane 1997 The impact of in vitro-in vivo relationships on product development Adv Exp Med Biol 423 241 260 9269501 10.1007/978-1-4684-6036-0-23 1:CAS:528:DyaK1cXmvFKl
4. EMA Note for guidance on quality of modified release products: A: Oral Dosage Forms B: Transdermal Dosage Forms, 2000; CPMP/QWP/604/96.
5. J Emami 2006 In vitro-in vivo correlation: from theory to applications J Pharm Pharmaceut Sci 9 169 189 1:CAS:528:DC%2BD28Xot1yjsLg%3D
6. FDA Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2003.
7. FDA Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 1997.
8. FDA Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In vitro Release Testing and In vivo Bioequivalence Documentation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 1997.
9. Farrell C, Hayes S. IVIVC for oral drug delivery: immediate release and extended release dosage forms in pharmaceutical product development. In: Chilukuri DM, Sunkara G, Young D, editors. In vitro-in vivo correlation. New York: Marcel Dekker; 2007. p. 125-40.
10. ICH Steering Committee, Draft consensus guideline on development Q8 step 4, August 2009.
11. LJ Leeson 1995 In vitro/in vivo correlations Drug Inf J 29 903 915 10.1177/009286159502900312
12. DT Mauger VM Chinchilli 1997 In vitro-in vivo relationships for oral extended-release drug products J Biopharm Stat 7 565 578 9358329 10.1080/10543409708835207 1:STN:280:DyaK1c%2FitlWltA%3D%3D
13. S Bigora D Piscitelli J Dowell J Butler C Farrell J Devane, et al. 1997 Use of nonlinear mixed effects modelling in the development of in vitro-in vivo correlations Adv Exp Med Biol 423 207 215 9269497 10.1007/978-1-4684-6036-0-19 1:CAS:528:DyaK1cXmvFGh
14. A Dunne C Gaynor J Davis 2005 Deconvolution based approach for level A in vivo-in vitro correlation modeling: statistical considerations Clin Res Reg Aff 22 1 14
15. A Dunne T O'Hara J Devane 1997 Approaches to IVIVR modelling and statistical analysis Adv Exp Med Biol 423 67 86 9269484 10.1007/978-1-4684-6036- 0-6 1:CAS:528:DyaK1cXmslKj
16. C Gaynor A Dunne J Davis 2008 A comparison of the prediction accuracy of two IVIVC modelling techniques J Pharm Sci 97 3422 3432 17990312 10.1002/jps.21220 1:CAS:528:DC%2BD1cXpsVOrtr4%3D
17. T O'Hara S Hayes J Davis J Devane T Smart A Dunne 2001 In vivo-in vitro (IVIVC) modeling incorporating a convolution step J Pharmacokinet Phar 28 277 298 10.1023/A:1011531226478
18. P Hemmingsen A-M Haahr C Gunnergaard J-M Cardot 2011 Development of a new type of prolonged release hydrocodone formulation based on Egalet® ADPREM technology using in vivo in vitro correlation Pharmaceutics 3 73 87 10.3390/pharmaceutics3010073 10.3390/pharmaceutics3010073 1:CAS:528: DC%2BC3MXjslSmsLc%3D
19. P Buchwald 2003 Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method J Pharm Pharmacol 55 495 504 12803771 10.1211/002235702847 1:CAS:528:DC%2BD3sXktlyisrk%3D
20. JA Dowell A Hussain J Devane D Young 1999 Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience J Pharm Sci 88 154 160 9874718 10.1021/js970148p 1:CAS:528:DyaK1cXntl2kt78%3D
21. Gillespie WR. Convolution-based approaches for in vitro-in vivo correlation modeling. In: Young D, Devane J, Butler J, editors. Advances in experimental medicine and biology, in vitro-in vivo correlations. New York: Plenum; 1997. p. 53-65.
22. H Kortejarvi J Malkki M Marvola M Yliperttula P Pajunen 2006 Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series J Pharm Sci 95 1595 1605 16732564 10.1002/jps.20592 1:CAS:528: DC%2BD28XmvVGltbc%3D
23. Rackley RJ. Examples of in vitro-in vivo relationships with a diverse range of quality. In: Young D, Devane J, Butler J, editors. Advances in experimental medicine and biology, in vitro-in vivo correlations. New York: Plenum; 1997. p. 1-16.
24. NIHS (National Institute of Health Sciences Japan) Guideline for Bioequivalence Studies of Generic Products, December, 2006.
25. NIHS (National Institute of Health Sciences Japan) Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms December, 2006.
26. Banakar UV, Makoid MC. Drug dissolution and bioavailability. Lancaster, PA: Technomic; 1994.
27. J-M Cardot E Beyssac M Alric 2007 In vitro-in vivo correlation Importance of dissolution in IVIVC Dis Tech 14 15 19 1:CAS:528:DC%2BD2sXksFWrtbg%3D
28. Rohrs BR, Skoug JW and Halstead GW. Dissolution assay development for in vitro-in vivo correlations: theory and case studies. Young D., Devane J., Butler J. editors. Advances in Experimental Medicine and Biology, In vitro-in vivo Correlations, Plenum, New York 1997;423:17-30.
29. J Marvola H Kanerva L Slot M Lipponen T Kekki H Hietanen, et al. 2004 Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system Int J Pharm 281 3 10 15288338 10.1016/j.ijpharm.2004.05.022 1:CAS:528:DC%2BD2cXmtFCmurs%3D
30. Gibaldi M, Prescott L. Handbook of clinical pharmacokinetics. New York: ADIS; 1983.
31. JG Wagner E Nelson 1963 Percent absorbed time plots derived from blood level and/or urinary excretion data J Pharm Sci 52 610 611 13998253 10.1002/jps.2600520629 1:STN:280:DyaF387ptVWhuw%3D%3D
32. H Lennernas 1997 Human intestinal permeability J Pharm Sci 87 403 410 10.1021/js970332a
33. MN Martinez GL Amidon 2002 A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J Clin Pharmacol 42 620 643 12043951 10.1177/00970002042006005 1:CAS:528:DC%2BD38Xks1OgsLc%3D
34. LX Yu GL Amidon 1999 A compartmental absorption and transit model for estimating oral drug absorption Int J Pharm 186 119 125 10486429 10.1016/S0378-5173(99)00147-7 1:CAS:528:DyaK1MXlvVWmtbg%3D
35. LX Yu 1999 An integrated model for determining causes of poor oral drug absorption Pharm Res 16 1883 1887 10644078 10.1023/A:1018911728161 1:CAS:528:DC%2BD3cXkt1entg%3D%3D
36. FDA Guidance for Industry : Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) August 2000.
37. R Lobenberg GL Amidon 2000 Modern bioavailability and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur J Pharm Biopharm 50 3 12 10840189 10.1016/S0939-6411(00)00091-6 1:CAS:528:DC%2BD3cXjslyju7g%3D
38. EMA, Guideline on the investigation of bioequivalence, CPMP/QWP/EWP/1401/98 Rev. 1, January 2010.